BioWorld MedTech

March 2, 2016

Nexstim facing uncertain future after stroke rehabilitation device trial fails

Nexstim Plc faces an uncertain future with its Navigated Brain Therapy (NBT) for stroke rehabilitation after a phase III study of the device failed to meet its primary endpoint. Read More

In releasing list of outstanding devices, China is promoting its med-tech sector

FDA posts September 2015 warning letter to Rewalk for 522 study

Savara so good: Aerovanc inhaled vancomycin nears pivotal with $20M series C

FDA decisions on Neuro-Spinal Scaffold propel Invivo's INSPIRE study, stock forward

Financings

Appointments & advancements

Daily M&A

Other news to note

Product briefs

Oncology Extra

Today's news in brief

BioWorld

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...